Co-Authors
This is a "connection" page, showing publications co-authored by Didier Raoult and Van Hoang.
Connection Strength
3.316
-
Does SARS-CoV-2 re-infection depend on virus variant? Clin Microbiol Infect. 2021 09; 27(9):1374-1375.
Score: 0.238
-
Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann. Int J Antimicrob Agents. 2021 Mar; 57(3):106306.
Score: 0.232
-
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited. Int J Antimicrob Agents. 2021 Jan; 57(1):106243.
Score: 0.230
-
Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load. Int J Antimicrob Agents. 2021 01; 57(1):106244.
Score: 0.230
-
Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. Int J Antimicrob Agents. 2021 01; 57(1):106237.
Score: 0.230
-
Response to advances statistical methods and designs for clinical trials for COVID-19. Int J Antimicrob Agents. 2021 01; 57(1):106235.
Score: 0.230
-
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. Int J Antimicrob Agents. 2021 Jan; 57(1):106239.
Score: 0.230
-
Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. Int J Antimicrob Agents. 2021 01; 57(1):106241.
Score: 0.230
-
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19. Int J Antimicrob Agents. 2021 Jan; 57(1):106242.
Score: 0.230
-
Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020 Jun; 39(6):1059-1061.
Score: 0.220
-
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020 Mar - Apr; 34:101663.
Score: 0.219
-
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul; 56(1):105949.
Score: 0.218
-
Correlation Between 3790 Quantitative Polymerase Chain Reaction-Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates. Clin Infect Dis. 2021 06 01; 72(11):e921.
Score: 0.119
-
SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence. J Clin Med. 2021 Jun 15; 10(12).
Score: 0.059
-
Clinical outcomes in COVID-19 patients infected with different SARS-CoV-2 variants in Marseille, France. Clin Microbiol Infect. 2021 Oct; 27(10):1516.e1-1516.e6.
Score: 0.059
-
Variations in respiratory pathogen carriage among a homeless population in a shelter for men in Marseille, France, March-July 2020: cross-sectional 1-day surveys. Eur J Clin Microbiol Infect Dis. 2021 Jul; 40(7):1579-1582.
Score: 0.058
-
Screening of SARS-CoV-2 among homeless people, asylum-seekers and other people living in precarious conditions in Marseille, France, March-April 2020. Int J Infect Dis. 2021 Apr; 105:1-6.
Score: 0.058
-
Long-term persistence of olfactory and gustatory disorders in COVID-19 patients. Clin Microbiol Infect. 2021 Jun; 27(6):931-932.
Score: 0.058
-
Coinfections with SARS-CoV-2 and other respiratory viruses in Southeastern France: A matter of sampling time. J Med Virol. 2021 04; 93(4):1878-1881.
Score: 0.057
-
Epidemiology of human common coronavirus acquisition in pilgrims. Travel Med Infect Dis. 2020 Sep - Oct; 37:101845.
Score: 0.056
-
Low prevalence of resistance genes in sheltered homeless population in Marseille, France, 2014-2018. Infect Drug Resist. 2019; 12:1139-1151.
Score: 0.051